Introduction
Primary cardiac lymphoma accounts for <2% of all primary cardiac tumours. It is uncommon in immunocompetent patients, often fatal and diagnosed at autopsy. Tumour usually involves the right heart chambers and pericardium. With advances in imaging, early diagnosis is possible and treatment including chemotherapy and surgery affords good prognosis. 
Case presentation
We present a 50-year-old woman with abdominal pain and fevers for 5 days. Computed tomography of the abdomen showed splenic and renal infarcts but no mass or vegetation was noted on echocardiography. Thoracic computed tomography divulged a large left ventricular filling defect. Cardiac magnetic resonance imaging delineated a 3.5 Â 4.5 cm anterobasal mass with frond-like projections and endocardial invasion without extracardiac involvement suggestive of a low-vascularity tumour. Echo-guided endomyocardial biopsy and minithoracotomy with needle biopsy were inconclusive. A sarcoid-protocol cardiac positron emission tomography-fluorodeoxyglucose scan showed focally elevated uptake in the basal anteroseptum without extracardiac uptake, supporting a malignant entity. This prompted open heart mass resection. Pathology revealed diffuse large B-cell lymphoma.
Introduction
Primary cardiac lymphoma (PCL) is a non-Hodgkin's lymphoma that involves the heart and/or pericardium. 1 It is rare, accounting for 2% of primary cardiac tumours 1,2 and often presents with non-specific clinical and imaging features, posing a diagnostic challenge. The tumour is less common in immunocompetent patients and usually involves the right heart chambers and pericardium. 3 Primary cardiac lymphoma should be distinguished from secondary neoplasms and from other primary cardiac tumours including myxoma (most common benign tumour) and angiosarcoma (most common malignant tumour). Cytology is paramount for definitive diagnosis. It is often
Learning points
• This case is a rare presentation of lymphoma exclusive to the left ventricle.
• It underscores the importance of keeping a broad differential, multimodality radiological approach for diagnostic work-up and multidisciplinary clinical approach.
• It illustrates an example of performing high-risk surgical resection for diagnostic and therapeutic purpose in a chemotherapy-responsive tumour. The success is accentuated by the patient's continued excellent outcome. The CT did not show vasculitis but revealed a filling defect in the left ventricle measuring 3.5 cm Â 4.5 cm, concerning for thrombus ( Figure 1 ). Cardiac magnetic resonance imaging (MRI) was performed for further tissue characterization and showed a poorly defined mass invading the anterior wall and septum with projections into the left ventricle ( Figure 2A -E). Late gadolinium enhancement imaging with long inversion time revealed a mass homogeneous with the myocardium, suggesting that this was not a thrombus. The mass was slightly hyperintense on T1 and T2 weighted sequences ( Figure 2C and D). Rest perfusion revealed mild appearance of vascularity ( Figure 2E ). Tissue characteristics by MRI suggested malignancy, but tissue biopsy was recommended for confirmation.
Guided by transoesophageal echocardiogram (TOE), left ventricular (LV) endomyocardial biopsy was attempted but was inconclusive as the procedure was aborted prematurely due to ventricular arrhythmias. Noted on TOE was a large and complex mass invading the anteroseptum ( Figure 3A -E), with attached smaller mobile echodensities causing intermittent obstruction of the left ventricular outflow tract ( Figure 3C -E). Cardiac positron emission tomography (PET) imaging was performed with 18F-fluorodeoxyglucose (FDG) to determine if the mass was indeed malignant. This was performed after a high-fat diet for 24 h and injection of heparin to suppress baseline myocardial glucose uptake. The PET imaging showed a focal area of increased FDG uptake in the basal anteroseptum of the left ventricle with a maximum standardized uptake value of 10.7, consistent with a malignant rather than benign mass (Figure 4) . A second biopsy attempted by left anterior mini-thoracotomy and needle biopsy failed to obtain adequate specimens primarily due to location of the mass on the septum. The patient was subsequently discharged in stable condition with outpatient appointments with the cardiac surgeon. However, she Owing to inconclusive biopsies, given the malignant appearance, and out of concern for further systemic emboli, complete resection was performed in a high risk open-heart surgery that included mitral valve repair. Pathology yielded diffuse large B-cell lymphoma (DLBCL) ( Figure 5 ). She completed six cycles of chemotherapy with R-EPOCH (rituximab þ etoposide þ prednisolone þ Oncovin/vincristine þ cyclophosphamide þ hydroxydaunorubicin). A PET scan before the third cycle showed no FDG-avid lesions. Repeat cardiac MRI 6 months post-resection and chemotherapy showed no residual mass ( Figure 2F) . At the time of this manuscript (more than a year from presentation), she is alive and has normal functional capacity.
Discussion
Isolated LV involvement of DLBCL is exceedingly rare. The unusual location of the tumour, lack of specific imaging characteristics, and clinical presentation with embolic phenomena made it a diagnostic challenge. The MRI suggested a malignant tumour, which was confirmed with high-intensity FDG uptake on PET imaging. Additionally, the PET scan showed no evidence of extracardiac disease. These findings confirmed the need for open biopsy and resection for diagnostic and therapeutic purposes. Prior studies recommend percutaneous endomyocardial biopsy for diagnosis because the tumour is commonly located in the right-sided chambers, and because surgical resection is not needed in this chemo-sensitive tumour. 3, 4 The left ventricular location of tumour in our patient required surgery for biopsy. Petrich et al. 3 report constitutional symptoms, heart failure, and pericardial effusion as the most common presenting symptoms and signs of PCL. Our patient interestingly presented with constitutional symptoms and systemic embolic phenomena. To our knowledge, this is the first report of a PCL presenting in this fashion, although there is a case report of mixed cardiac myxoma and lymphoma presenting with peripheral emboli. 5 Unlike PCL, cardiac metastasis from extracardiac lymphoma is more common, and they largely occur in immunocompromised patients such as in HIV patients. Pericardial invasion and associated pericardial effusion is often present. 6 Our patient was immunocompetent, was HIV negative, and did not have pericardial involvement or effusion (effusion and tamponade noted under case description was iatrogenic post-biopsy).
Unlike other malignancies such as sarcomas, lymphomas are reported to lack areas of central necrosis and haemorrhage on MRI. Consequently, they are typically homogeneous and isointense on T1-and T2-weighted imaging with minimal contrast uptake at late gadolinium enhancement (LGE). 6 Characteristics of other tumours are outlined in Table 1 . Our patient's MRI showed slightly hyperintense T1-and T2-weighted images with no uptake on LGE (Figure 2) . The findings neither fit the pattern reported for lymphomas, sarcomas, or myxomas. Of note, prior reports are based on PCL affecting rightsided chambers while our report highlights imaging characteristics in LV PCL-which may not follow previously reported patterns. Hence, FDG-PET was performed for confirmation of malignancy before undertaking high-risk open surgical biopsy. The case not only brings forth a rare clinical entity, but also underscores the challenges of tissue characterization of tumours even with multimodality imaging. Despite the lack of malignant findings on initial percutaneous biopsy, the decision to pursue high-risk open-heart resection was based on strong evidence of malignancy by FDG-PET imaging. The lack of extracardiac involvement made cardiac tissue diagnosis imperative and proved highly effective for treatment -especially because the tumour is highly sensitive to rituximab-based chemotherapy.
3,4
Patient's perspective Our case was an extraordinary learning experience from a medical and humanitarian perspective. The patient was initially disheartened upon realizing that her seemingly benign presentation had turned into the dreadful possibility of a malignant cardiac tumour. The difficulties experienced by the medical team due to unsuccessful biopsies further tested her conviction. She showed exemplary courage and placed her faith in our specialists. With her determination, dedicated support from her family and integration of our care-teams, a successful outcome was facilitated. She was very satisfied with the outcome, and with the frequent communication and reassurance she received from her caretakers. She has remained compliant with follow-up visits and has completed her chemotherapy sessions. She is 
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